Ellen J. Kim - Faculty Biosketch

Ellen J. Kim, MD

Professor of Dermatology at the Hospital of the University of Pennsylvania

Department: Dermatology

Contact information

Department of Dermatology
Perelman School of Medicine at the University of Pennsylvania
Room 721, 7th Floor - South Tower
Perelman Center for Advanced Medicine
3400 Civic Center Boulevard
Philadelphia, PA 19104

Office: 215-662-2737
Fax: 215-615-4966

Education:
A.B. (East Asian Studies)
Harvard University, 1991.
M.D.
University of Pennsylvania, 1996.

Links
Official Website of the Department of Dermatology, University of Pennsylvania

Post-Graduate Training
Intern in Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 1996-1997.
Resident in Dermatology, Boston University School of Medicine/Tufts University School of Medicine, Boston, MA, 1997-2000.
Research Fellow, Department of Dermatology, Boston University School of Medicine, Boston, MA, 2000-2002.

Certifications
American Board of Dermatology (recertified 2020), 2000.

Permanent link

> Perelman School of Medicine > Faculty > Details

Description of Research Expertise

Clinical trials for cutaneous T-cell lymphoma (CTCL)

Description of Clinical Expertise

Cutaneous Lymphomas (T-cell and B-cell) and lymphoproliferative disorders
Graft vs Host Disease
Extracorporeal Photopheresis

Selected Publications

Marshall A, Kassim S, Brown-Korsah J, Raymundo C, Chang C, Hippe DS, Kim EJ, Shinohara MM.: Black patients with Mycosis fungoides and Sézary Syndrome experience worse health-related quality of life: A cross-sectional study. Journal of the American Academy of Dermatology 2025-05-01. J Am Acad Dermatol. 92(5): 1100-1102, May 2025.

Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK. : Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome. J Am Acad Dermatol. 92(3): 634-636, Mar 2025.

Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK.: Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome. J Am Acad Dermatol Nov 2024 Notes: doi: 10.1016/j.jaad.2024.10.095.

Villasenor-Park J, Chung J, Kim EJ: Cutaneous B-cell Lymphomas/Cutaneous Oncology. Hematology Oncology Clinics. Fisher D (eds.). Elsevier, 38(5): 1111, October 2024.

Silva GS, Kim EJ, Barta SK, Chung J: Immune-related adverse events associated with mogamulizumab: a comprehensive review of the literature. Expert Rev Anticancer Ther 24(9): 819-827, Sep 2024 Notes: doi: 10.1080/14737140.2024.2379914.

Asare C, Chen J, Ottevanger R, Scarisbrick J, Olsen EA, Tawa M, Thornton S, Kim E, Khan N, Larocca C, Shinohara MM. : Systematic literature review to identify patient-reported outcome measures for patients with cutaneous T-cell lymphoma. International Dermatology Outcomes Measures 11th Annual Meeting, Washington D.C. April 2024.

Rastogi S, Kim EJ, Gelfand JM, Loren AW, Baumrin E: Chronic graft-versus-host disease-associated muscle cramps: severity and response to immunomodulatory therapies Transplant Cell Ther 24, Jan 2024 Notes: doi: 10.1016/j.jtct.2023.12.674. Epub ahead of print.

Weiner DW, Rastogi S, Lewis DJ, Cohen L, Choi S, Vittorio CC, Haun PL, Samimi SS, Villasenor-Park J, Bhansali RS, Chong EA, Landsburg DJ, Nasta SD, Schuster, Svoboda J, Kim EJ, Rook AH, Barta SK.: Mogamulizumab Multimodality Therapy with Systemic Retinoids, Interferon, or Extracorporeal Photopheresis for Advanced Cutaneous T-Cell Lymphoma. Dermatologic Therapy Dec 2023 Notes: https://doi.org/10.1155/2023/7625926.

Bagot M, Kim YH, Geskin LJ, Ortiz-Romero P, Kim E, Mehta-Shah N, Dereure O, Oro S, Beylot-barry M, Dalle S, Jacobsen E, Lansigan F, Ram-Wolff C, Khodadoust MS, Battistella M, Gru A, Moins-Teisserenc H, Zinzani PL, Viott J, Paiva C, Muller M, Porcu P.: Lacutumab in Patients with Relapsed and Refractory Sezary Syndrome: Results from the Tellomak Phase 2 Trial. American Society of Hematology Annual Meeting, San Diego, CA Dec 2023.

Polgione B, Alexander-Savino CV, Kim EJ, Mangold AR, Desimone J, Wong H, Rumage AT, Donini O, Haulenbeek A, Schaber CJ, Straube R, Pullion C, Rook AH.: HyBryte™ Use in Early-Stage Cutaneous T-cell Lymphoma Front Drug Discov 3, Nov 2023.